Cardiology device trials' use of independent clinical committees encouraged by FDA -- ODE's Zuckerman.
This article was originally published in The Gray Sheet
Executive SummarySTUDY BIAS IN "HIGH PROFILE" CARDIOLOGY DEVICE TRIALS should be addressed by independent clinical events committees, FDAers emphasized at a recent Food & Drug Law Institute workshop in Washington, D.C.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.